(Ketamine + midazolam) is under clinical development by Melt Pharmaceuticals and currently in Phase II for Sedation. According to GlobalData, Phase II drugs for Sedation have a 91% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Ketamine + midazolam)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Ketamine + midazolam) overview

A fixed dose combination of ketamine and midazolam (MELT-100) is under development for the treatment of conscious sedation in medical procedures, pain and acute claustrophobia. The drug candidates are formulated as tablet and administered through sublingual route. Ketamine acts by targeting N-methyl-D-aspartate (NMDA) receptors and midazolam acts by targeting gamma-aminobutyric acid (GABA) A receptor. It is being developed based on Zydis delivery technology. 

Melt Pharmaceuticals overview

Melt Pharmaceuticals is dedicated to the development of innovative approaches to procedural sedation and analgesia for short-term medical operations. The company is headquartered in United States.

For a complete picture of (Ketamine + midazolam)’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.